JP7733000B2 - アリピプラゾール治療の投薬開始のための方法 - Google Patents

アリピプラゾール治療の投薬開始のための方法

Info

Publication number
JP7733000B2
JP7733000B2 JP2022559750A JP2022559750A JP7733000B2 JP 7733000 B2 JP7733000 B2 JP 7733000B2 JP 2022559750 A JP2022559750 A JP 2022559750A JP 2022559750 A JP2022559750 A JP 2022559750A JP 7733000 B2 JP7733000 B2 JP 7733000B2
Authority
JP
Japan
Prior art keywords
aripiprazole
formulation
oral
patient
depot
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520004A5 (https=
JP2023520004A (ja
Inventor
ハーリン，マシュー
ワン，シャオフォン
ワン，ヤンリン
ラウフィニア，アラシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7733000(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2023520004A publication Critical patent/JP2023520004A/ja
Publication of JP2023520004A5 publication Critical patent/JP2023520004A5/ja
Priority to JP2025137577A priority Critical patent/JP2025176037A/ja
Application granted granted Critical
Publication of JP7733000B2 publication Critical patent/JP7733000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
JP2022559750A 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法 Active JP7733000B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025137577A JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025137577A Division JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Publications (3)

Publication Number Publication Date
JP2023520004A JP2023520004A (ja) 2023-05-15
JP2023520004A5 JP2023520004A5 (https=) 2025-05-21
JP7733000B2 true JP7733000B2 (ja) 2025-09-02

Family

ID=75581573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022559750A Active JP7733000B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法
JP2022559751A Active JP7584535B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法
JP2024193628A Pending JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022559751A Active JP7584535B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法
JP2024193628A Pending JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Country Status (16)

Country Link
US (6) US20230129919A1 (https=)
EP (3) EP4467194A3 (https=)
JP (4) JP7733000B2 (https=)
KR (3) KR20220161402A (https=)
CN (3) CN115379842A (https=)
AU (2) AU2021248212A1 (https=)
BR (2) BR112022018721A2 (https=)
CA (3) CA3163321C (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012354A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TW202523329A (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére
CA3197997A1 (en) 2023-03-17 2025-01-23 Otsuka Pharmaceutical Co., Ltd. METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514751A (ja) 2012-04-23 2015-05-21 大塚製薬株式会社 注射製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
UA96342C2 (en) 2007-06-25 2011-10-25 Оцука Фармасьютикал Ко., Лтд. Microspheres having core/shell structure
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP4082546A1 (en) 2017-05-16 2022-11-02 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
HUE069157T2 (hu) 2020-04-01 2025-02-28 Otsuka Pharma Co Ltd Eljárások aripiprazol kezelések adagoláskezdésére

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015514751A (ja) 2012-04-23 2015-05-21 大塚製薬株式会社 注射製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT REVIEW OF CLINICAL PHARMACOLOGY，2016年，VOL.9,NO.2，pp.169-186
Journal of Clinical Psychopharmacology，2018年，Vol.38, No. 5，pp.435-441

Also Published As

Publication number Publication date
JP2025020306A (ja) 2025-02-12
EP3941470A1 (en) 2022-01-26
KR20240165486A (ko) 2024-11-22
TW202523329A (zh) 2025-06-16
EP4467194A3 (en) 2025-01-08
JP7584535B2 (ja) 2024-11-15
US20220160621A1 (en) 2022-05-26
MX2022012353A (es) 2022-10-31
KR102732030B1 (ko) 2024-11-20
AU2021248212A1 (en) 2022-12-01
CA3212191A1 (en) 2021-10-07
CA3163321C (en) 2023-12-19
CN115379842A (zh) 2022-11-22
EP4467194A2 (en) 2024-11-27
CA3163321A1 (en) 2021-10-07
WO2021201239A1 (en) 2021-10-07
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
US20240374506A1 (en) 2024-11-14
EP4125903B1 (en) 2024-10-09
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
CN115397420A (zh) 2022-11-25
US20230129919A1 (en) 2023-04-27
TWI865760B (zh) 2024-12-11
KR20220161402A (ko) 2022-12-06
US20260115131A1 (en) 2026-04-30
JP2023520004A (ja) 2023-05-15
EP4125903C0 (en) 2024-10-09
JP2023519425A (ja) 2023-05-10
TW202200141A (zh) 2022-01-01
JP2025176037A (ja) 2025-12-03
US20260034053A1 (en) 2026-02-05
TWI906279B (zh) 2025-12-01
EP4125903A1 (en) 2023-02-08
PL4125903T3 (pl) 2025-02-03
BR112022018721A2 (pt) 2022-11-01
AU2021245713A1 (en) 2022-12-01
HUE069157T2 (hu) 2025-02-28
US20230225962A1 (en) 2023-07-20
WO2021201238A1 (en) 2021-10-07
ES2995466T3 (en) 2025-02-10
CA3136727A1 (en) 2021-10-07
MX2022012354A (es) 2022-10-31
CN119792290A (zh) 2025-04-11
BR112022018647A2 (pt) 2022-11-08

Similar Documents

Publication Publication Date Title
JP7733000B2 (ja) アリピプラゾール治療の投薬開始のための方法
US12251381B2 (en) Aripiprazole dosing strategy
HK40120297A (en) Methods for dose initiation of aripiprazole treatments
HK40122823A (zh) 阿立哌唑治疗的剂量起始方法
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
HK40081123B (en) Methods for dose initiation of aripiprazole treatments
WO2024225441A1 (en) Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole
HK40080999A (en) Methods for dose initiation of aripiprazole treatments
JP2026514220A (ja) アリピプラゾールを用いた統合失調症または双極性障害ｉ型の治療における投与開始
HK40128859A (zh) 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250821

R150 Certificate of patent or registration of utility model

Ref document number: 7733000

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150